Close Menu

NEW YORK – Guardant Health said today that it has priced an underwritten public offering of 11.5 million shares of its common stock at a $84 per share.

The offering is expected to close on June 4.

Guardant is selling 3,750,000 of the shares and SoftBank Investment Advisers is selling the other 7,750,000 shares. The total, for which JP Morgan Securities is acting as sole book-running manager, was increased from a previously announced 10 million shares of common stock.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.